REGENXBIO Announces Presentations at the 19th Annual WORLDSymposium™ 2023
New interim data from Phase I/I/III trial of RGX-121 for the treatment of MPS II and Phase I/II trial of RGX-111 for the treatment of MPS I to be presented ROCKVILLE, Md., Feb. 17, 2023 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) today announced that three oral and eight poster…
Comments Off on REGENXBIO Announces Presentations at the 19th Annual WORLDSymposium™ 2023